GreenRoc now on the EU radar after presentation on Amitsoq at the Greenland Business Mission. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksAbingdon Healt. Regulatory News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 9.00
Ask: 9.50
Change: 0.00 (0.00%)
Spread: 0.50 (5.556%)
Open: 9.00
High: 9.25
Low: 9.00
Prev. Close: 9.25

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic collaboration with DeepVerge plc

29 Mar 2022 07:00

RNS Number : 3116G
Abingdon Health PLC
29 March 2022
 

Abingdon Health plc

("Abingdon" or "the Company")

 

Strategic collaboration with DeepVerge plc

Focused on the development, manufacturing and commercialisation of lateral flow tests to support DeepVerge's Modern Water and Life Science divisions

 

York, U.K. 29 March 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has signed a Memorandum of Understanding ("MoU") with DeepVerge plc (AIM: DVRG) ("DeepVerge"), an environmental and life science group that develops and applies AI and IoT technology for the analysis and identification of bacteria, virus and toxins, leading to a commercial agreement for development and manufacture of a range of lateral flow tests ("LFTs") for DeepVerge's Modern Water and Life Science divisions.

 

The MoU has been signed to enable the potential integration of the respective technologies of both DeepVerge and Abingdon. DeepVerge and Abingdon intend to enter into a longer-term commercial agreement, with Abingdon manufacturing and DeepVerge commercialising the new products through its production, sales, marketing and distribution channel partners around the world.

 

Modern Water

Modern Water is the environmental division of DeepVerge that has developed and commercialised cutting-edge technology focused on monitoring of contaminated water and decontamination of wastewater. Abingdon and DeepVerge will work on the development of LFT devices to detect dangerous pathogens and chemicals in household drinking and wastewater. This will add an extra layer of detection to the current Modern Water range of equipment and services by incorporating an LFT into a hand-held mobile unit. The results of these LFT devices can be digitally scanned using a mobile app, with the potential to incorporate Abingdon's proprietary AppDx® technology.

 

Future potential developments for water testing that are complementary to the current Modern Water portfolio include the pepper mottle mosaic virus as a potential marker for human faecal matter in water and the automated multiplexing project bringing in influenza A, influenza B, Cryptosporidium etc. into the testing format on a hand-held device.

 

Life Science

Abingdon and DeepVerge will also collaborate on the development of new lateral flow tests to be added to DeepVerge's life science home test portfolio, including hormone analysis related to menopause and associated skin changes, stress levels (cortisol), vitamin D, and other health markers related to conditions including diabetes, heart and liver function.

 

Gerard Brandon, CEO of DeepVerge plc, commented:

"DeepVerge's business model is built on collaborating and cooperating with partners such as Abingdon Health who have technologies and large production capacity to deliver solutions to major societal problems such as water contamination and the identification of human biomarkers for a range of health conditions. Surveillance and testing of waterways for the presence of bacteria and viruses has gained worldwide recognition and this collaboration is yet another example of the diagnostics industry working together to rapidly bring effective solutions in the increasing global health risks."

 

Chris Yates, CEO of Abingdon Health plc, commented: 

"We are delighted to be working with the DeepVerge team to deliver a range of lateral flow tests that have the ability to monitor household water and wastewater for a range of dangerous pathogens, as well as providing innovative new tests to supplement DeepVerge's life science home test portfolio. Our facilities in the UK have a large capacity and we are excited to develop these new products to play a key role in maintaining health in the home."

 

Enquiries:

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Melanie Ross, Chief Financial Officer

Christopher Hand, Non-Executive Chairman

Singer Capital Markets (Sole Broker and Nominated Adviser)

Tel: +44 (0)20 7496 3000

Shaun Dobson, Peter Steel, Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

Alice Woodings

Mob: +44 (0)7407 804 654

 

About Abingdon Health plc (www.abingdonhealth.com)

 

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

 

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

 

 Founded in 2008, Abingdon Health is headquartered in York, England.

 

About DeepVerge plc (www.deepverge.com)

 

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins; Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUWARRUWUOUUR
Date   Source Headline
4th Oct 20247:00 amRNSNotice of Results
29th Aug 20247:00 amRNSResults of the Retail Offer
27th Aug 20249:26 amRNSTR - 1
20th Aug 20243:44 pmRNSTR-1
19th Aug 20241:48 pmRNSTR-1
19th Aug 20241:48 pmRNSTR-1
19th Aug 20241:45 pmRNSTR-1
19th Aug 20249:00 amRNSRetail Offer Launch
15th Aug 20243:50 pmRNSCompletion of Acquisition of Compliance Solutions
12th Aug 202410:41 amRNSResult of General Meeting and Total Voting Rights
25th Jul 202411:52 amRNSResult of Placing
24th Jul 20244:51 pmRNSProposed Acquisition and Placing Notice of GM
15th Jul 20247:00 amRNSChange of Nominated Adviser and Broker
9th Jul 20247:00 amRNSTrading Update
31st May 20247:00 amRNSTotal Voting Rights – 31 May 2024
15th May 20247:00 amRNSLaunch of the Saliva Pregnancy self-test in Boots
8th May 20247:00 amRNSChange of Nominated Adviser and Sole Broker
7th May 20247:00 amRNSAcquisition of IVDeology Holdings Limited
25th Mar 20247:00 amRNSDesign freeze completion & strategic partnership
20th Mar 20247:00 amRNSLaunch of OEM self-tests in Boots
15th Mar 20241:00 pmRNSCEO Interview
14th Mar 20247:00 amRNSInterim Results
11th Mar 20248:53 amRNSNotice of Results
11th Jan 20247:01 amRNSUpdate to Shareholder Concert Parties
11th Jan 20247:00 amRNSTrading Update
15th Dec 202310:15 amRNSResult of AGM
15th Dec 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSNotice of Annual General Meeting
25th Oct 20237:00 amRNSDirector/PDMR Shareholding
24th Oct 20237:01 amRNSAward of Options under LTIP
24th Oct 20237:00 amRNSAppointment of Interim Finance Director
18th Oct 20237:00 amRNSDirectorate Change
17th Oct 20237:00 amRNSFinal Results
11th Oct 20237:00 amRNSNotice of Results
7th Sep 20237:00 amRNSPartnership with Morrama
30th Aug 20237:00 amRNSAgreed changes to Concert Party
15th Aug 20237:00 amRNSSalistick™ to be launched in Tesco
6th Jul 20237:00 amRNSTrading Update
19th Jun 20237:00 amRNSLaunch of Salistick™ saliva pregnancy test
31st Mar 20237:00 amRNSInterim Results
24th Mar 202312:30 pmRNSNotice of Results
20th Mar 20237:00 amRNSSenzo & Abingdon enter into strategic partnership
7th Mar 20237:00 amRNSAppDx® granted further patent
1st Mar 20237:00 amRNSDirector Share Transfer to Trust
28th Feb 20239:05 amRNSSecond Price Monitoring Extn
28th Feb 20239:00 amRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSTrading Update
19th Dec 202210:29 amRNSResult of AGM
19th Dec 20227:01 amRNSAward of Options under new LTIP Scheme
19th Dec 20227:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Track Your Investments

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.